U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07062198) titled 'Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease' on June 11.
Brief Summary: This randomised, double-blinded, placebo-controlled study aims to establish metabolic improvements in subjects diagnosed with Alzheimer's Disease (AD) by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine.
Participants will take the drug CMA2 or a placebo twice a day for 26 weeks. They will visit the clinic 4 times for checkups and tests.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Alzheimer Disease
Interventi...